vs
Side-by-side financial comparison of AlTi Global, Inc. (ALTI) and BillionToOne, Inc. (BLLN). Click either name above to swap in a different company.
AlTi Global, Inc. is the larger business by last-quarter revenue ($86.6M vs $83.5M, roughly 1.0× BillionToOne, Inc.). BillionToOne, Inc. runs the higher net margin — 6.8% vs -15.1%, a 22.0% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs 87.0%). BillionToOne, Inc. produced more free cash flow last quarter ($6.5M vs $-52.2M).
Cristal Global is the world's second-largest producer of titanium dioxide and a leading producer of titanium chemicals. It was formed when The National Titanium Dioxide Company Ltd. combined with Millennium Chemicals. The headquarters are in Jeddah, Saudi Arabia. It is a significant shareholder in Bemax, the world’s 5th largest TiO2 feedstock producer.
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
ALTI vs BLLN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.6M | $83.5M |
| Net Profit | $-13.1M | $5.7M |
| Gross Margin | — | 69.9% |
| Operating Margin | -2.1% | 11.5% |
| Net Margin | -15.1% | 6.8% |
| Revenue YoY | 87.0% | 117.4% |
| Net Profit YoY | 75.6% | 138.3% |
| EPS (diluted) | — | $0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.6M | — | ||
| Q3 25 | $57.2M | $83.5M | ||
| Q2 25 | $53.1M | — | ||
| Q1 25 | $58.0M | — | ||
| Q4 24 | $46.3M | — | ||
| Q3 24 | $51.8M | $38.4M | ||
| Q2 24 | $49.5M | — | ||
| Q1 24 | $50.8M | — |
| Q4 25 | $-13.1M | — | ||
| Q3 25 | $-84.1M | $5.7M | ||
| Q2 25 | $-24.4M | — | ||
| Q1 25 | $1.9M | — | ||
| Q4 24 | $-53.8M | — | ||
| Q3 24 | $-72.5M | $-14.9M | ||
| Q2 24 | $-6.4M | — | ||
| Q1 24 | $29.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 69.9% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 52.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -2.1% | — | ||
| Q3 25 | -49.8% | 11.5% | ||
| Q2 25 | -56.7% | — | ||
| Q1 25 | -23.3% | — | ||
| Q4 24 | -42.7% | — | ||
| Q3 24 | -18.4% | -32.9% | ||
| Q2 24 | -30.2% | — | ||
| Q1 24 | -28.9% | — |
| Q4 25 | -15.1% | — | ||
| Q3 25 | -147.0% | 6.8% | ||
| Q2 25 | -45.9% | — | ||
| Q1 25 | 3.3% | — | ||
| Q4 24 | -116.1% | — | ||
| Q3 24 | -140.0% | -38.8% | ||
| Q2 24 | -12.9% | — | ||
| Q1 24 | 58.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $0.10 | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.04 | — | ||
| Q4 24 | $-0.71 | — | ||
| Q3 24 | $-0.88 | $-1.47 | ||
| Q2 24 | $-0.18 | — | ||
| Q1 24 | $0.18 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.2M | $195.2M |
| Total DebtLower is stronger | $883.0K | $55.0M |
| Stockholders' EquityBook value | $600.1M | $-239.5M |
| Total Assets | $1.2B | $327.5M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $41.2M | — | ||
| Q3 25 | $35.8M | $195.2M | ||
| Q2 25 | $42.4M | — | ||
| Q1 25 | $52.8M | — | ||
| Q4 24 | $64.4M | — | ||
| Q3 24 | $220.6M | — | ||
| Q2 24 | $60.0M | — | ||
| Q1 24 | $134.2M | — |
| Q4 25 | $883.0K | — | ||
| Q3 25 | $586.0K | $55.0M | ||
| Q2 25 | $673.0K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $128.4M | — | ||
| Q2 24 | $164.0M | — | ||
| Q1 24 | $183.7M | — |
| Q4 25 | $600.1M | — | ||
| Q3 25 | $607.2M | $-239.5M | ||
| Q2 25 | $685.4M | — | ||
| Q1 25 | $665.2M | — | ||
| Q4 24 | $658.4M | — | ||
| Q3 24 | $707.0M | $-242.9M | ||
| Q2 24 | $540.2M | — | ||
| Q1 24 | $510.9M | — |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | $327.5M | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.3B | — |
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.18× | — | ||
| Q2 24 | 0.30× | — | ||
| Q1 24 | 0.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-51.4M | $13.8M |
| Free Cash FlowOCF − Capex | $-52.2M | $6.5M |
| FCF MarginFCF / Revenue | -60.3% | 7.7% |
| Capex IntensityCapex / Revenue | 0.9% | 8.8% |
| Cash ConversionOCF / Net Profit | — | 2.42× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-51.4M | — | ||
| Q3 25 | $-53.5M | $13.8M | ||
| Q2 25 | $-19.9M | — | ||
| Q1 25 | $-30.2M | — | ||
| Q4 24 | $-50.7M | — | ||
| Q3 24 | $-4.9M | — | ||
| Q2 24 | $-30.2M | — | ||
| Q1 24 | $-15.5M | — |
| Q4 25 | $-52.2M | — | ||
| Q3 25 | — | $6.5M | ||
| Q2 25 | $-20.0M | — | ||
| Q1 25 | $-31.0M | — | ||
| Q4 24 | $-58.2M | — | ||
| Q3 24 | $-9.4M | — | ||
| Q2 24 | $-31.2M | — | ||
| Q1 24 | $-15.7M | — |
| Q4 25 | -60.3% | — | ||
| Q3 25 | — | 7.7% | ||
| Q2 25 | -37.6% | — | ||
| Q1 25 | -53.4% | — | ||
| Q4 24 | -125.7% | — | ||
| Q3 24 | -18.2% | — | ||
| Q2 24 | -63.2% | — | ||
| Q1 24 | -30.9% | — |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.0% | 8.8% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 16.3% | — | ||
| Q3 24 | 8.7% | — | ||
| Q2 24 | 2.2% | — | ||
| Q1 24 | 0.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.42× | ||
| Q2 25 | — | — | ||
| Q1 25 | -15.80× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.52× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALTI
| Management Advisory Fees | $51.1M | 59% |
| Other | $32.7M | 38% |
| Distributions From Investments | $2.9M | 3% |
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
